PriceTargets.com logo

Zevra Therapeutics - KMPH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/28/2023 01:00 AM ET
+0 (0.00%)
Get New Zevra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KMPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KMPH

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Zevra Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for KMPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Zevra Therapeutics. This rating has held steady since October 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/17/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00
11/10/2022Canaccord Genuity GroupLower Target$20.00 ➝ $19.00
9/15/2022Canaccord Genuity GroupInitiated CoverageBuy
8/17/2022HC WainwrightLower TargetBuy$11.00 ➝ $10.00
1/31/2022HC WainwrightUpgradeNeutral ➝ Buy$10.00 ➝ $11.00
11/12/2021HC WainwrightReiterated RatingHold$10.00
3/10/2021HC WainwrightReiterated RatingBuy ➝ Neutral$24.00 ➝ $12.00
3/4/2021HC WainwrightDowngradeBuy ➝ Neutral
1/25/2021Roth CapitalInitiated CoverageBuy
8/18/2020HC WainwrightReiterated RatingBuy$1.50
5/20/2020HC WainwrightLower TargetBuy$2.50 ➝ $1.50
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zevra Therapeutics logo
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $5.51
Low: $4.48
High: $6.27

52 Week Range

Now: N/A

Volume

64,100 shs

Average Volume

189,500 shs

Market Capitalization

$200.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Zevra Therapeutics?

The following equities research analysts have issued research reports on Zevra Therapeutics in the last year: StockNews.com.
View the latest analyst ratings for KMPH.

What is the current price target for Zevra Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Zevra Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zevra Therapeutics in the next year.
View the latest price targets for KMPH.

What is the current consensus analyst rating for Zevra Therapeutics?

Zevra Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KMPH.

What other companies compete with Zevra Therapeutics?

Other companies that are similar to Zevra Therapeutics include Avid Bioservices, Keros Therapeutics, Kura Oncology, Immunome and Tyra Biosciences. Learn More about companies similar to Zevra Therapeutics.

How do I contact Zevra Therapeutics' investor relations team?

Zevra Therapeutics' physical mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company's listed phone number is (321) 939-3416 and its investor relations email address is [email protected]. The official website for Zevra Therapeutics is www.kempharm.com. Learn More about contacing Zevra Therapeutics investor relations.